Vista Pharmaceuticals reports FY26 net loss of ₹1,206.12 lakh
Vista Pharmaceuticals Limited reported a widened net loss of ₹1,206.12 lakh for FY26, with revenue from operations dropping to ₹539.95 lakh from ₹1,007.46 lakh in the previous year. The company recognised an impairment allowance of ₹821.74 lakh on trade receivables and issued convertible share warrants raising ₹307.50 lakh. Despite five consecutive years of losses and negative working capital, the Board affirmed the going concern status based on net worth and promoter support.
*this image is generated using AI for illustrative purposes only.
Vista Pharmaceuticals Limited reported a widened net loss of ₹1,206.12 lakh for the financial year ended March 31, 2026, compared to a net loss of ₹464.87 lakh in the previous year. The company's revenue from operations fell to ₹539.95 lakh from ₹1,007.46 lakh in FY25. For the quarter ended March 31, 2026, the company reported a net loss of ₹586.29 lakh with zero revenue from operations.
The Board of Directors approved the audited standalone financial results for the quarter and year ended March 31, 2026, at a meeting held on May 29, 2026. The statutory auditors, M/s. A.M Reddy & D.R. Reddy, issued an unmodified opinion on the financial results. Additionally, the Board appointed M/s. LMN & Co., Chartered Accountants, as internal auditors for the financial year 2026-27.
Financial Performance
The company's total income for FY26 stood at ₹571.45 lakh, a decrease from ₹1,051.52 lakh in the previous year. Total expenses increased to ₹2,186.58 lakh from ₹1,580.51 lakh in FY25. The basic and diluted earnings per share for FY26 were reported as a loss of ₹1.96 per equity share, compared to a loss of ₹0.79 per share in the previous year.
| Metric | FY26 (₹ in lakh) | FY25 (₹ in lakh) |
|---|---|---|
| Revenue from operations | 539.95 | 1,007.46 |
| Total Income | 571.45 | 1,051.52 |
| Total Expenses | 2,186.58 | 1,580.51 |
| Net Profit/Loss | (1,206.12) | (464.87) |
| Basic EPS | (1.96) | (0.79) |
Key Disclosures
During the year, the company recognised an impairment allowance of ₹821.74 lakh on trade receivables, which were subsequently written off due to a lack of reasonable certainty of recovery. The company also issued 10,240,998 convertible share warrants and received 25% of the upfront subscription amounting to ₹307.50 lakh.
The financial statements were prepared on a going concern basis, despite the company incurring losses for the fifth consecutive year and having negative working capital of ₹133.86 lakh. The Board cited factors such as positive net worth of ₹3,644.08 lakh, promoter support of ₹581.34 lakh, and capital work-in-progress of ₹1,061.21 lakh as reasons supporting the company's ability to continue operations.
Historical Stock Returns for Vista Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.66% | -7.10% | -1.35% | -11.69% | -38.14% | -35.87% |
What specific strategies will management implement to reverse the five-year trend of consecutive losses and declining revenue?
How does the company plan to address the liquidity challenges posed by negative working capital and zero revenue in the final quarter?
What operational milestones need to be achieved to convert the ₹1,061.21 lakh capital work-in-progress into generating income?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
